BUDGET IMPACT OF NEWLY APPROVED DRUGS BY THE SICILIAN DRUG FORMULARY COMMITTEE: AN INTRODUCTIVE ANALYSIS

被引：0
|
作者：
Aiello, A. [1 ]
D'Ausilio, A. [1 ]
Pizzimenti, V [2 ]
Formica, D. [2 ]
Sultana, J. [2 ]
Lucchesi, S. [3 ]
Ientile, V [2 ]
Toumi, M. [4 ]
Trifiro, G. [3 ]
机构：
[1] Creativ Ceut, Milan, Italy
[2] AOU Policlin G Martino, Messina, Italy
[3] Univ Messina, Messina, Italy
[4] Aix Marseille Univ, Marseille, France
来源：
VALUE IN HEALTH | 2017年 / 20卷 / 09期
关键词：
D O I：
10.1016/j.jval.2017.08.1631
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
PHP97
引用
收藏
页码：A669 / A669
页数：1
相关论文
共 50 条
  • [41] THE ECONOMIC IMPACT OF ADDING CEFTAROLINE FOSAMIL TO HOSPITAL FORMULARY FOR COMMUNITY ACQUIRED BACTERIAL PNEUMONIA: A HOSPITAL BUDGET IMPACT ANALYSIS IN THE UNITED STATES
    Huang, X. Y.
    Lodise, T.
    Friedland, D.
    Beresford, E. J.
    VALUE IN HEALTH, 2012, 15 (04) : A238 - A238
  • [42] Estimation of usage of new drug after reimbursement for budget impact analysis
    Park, S. E.
    Lee, S. M.
    Yim, E. Y.
    Choi, H. W.
    Choi, D. H.
    Lim, S. H.
    Yi, S. Y.
    Choi, M. R.
    VALUE IN HEALTH, 2008, 11 (03) : A33 - A33
  • [43] BUDGET IMPACT ANALYSIS OF ANTIEPILEPTIC DRUGS IN THE TREATMENT OF LENNOX-GASTAUT SYNDROME
    Skornicki, M.
    Clements, K. M.
    O'Sullivan, A. K.
    VALUE IN HEALTH, 2012, 15 (04) : A141 - A142
  • [44] BUDGET IMPACT ANALYSIS OF ACEI AND ARBS II DRUGS IN PATIENTS WITH ARTERIAL HYPERTENSION
    Tolordava, G.
    Yagudina, R.
    Arinina, E.
    VALUE IN HEALTH, 2018, 21 : S100 - S100
  • [45] The Budget Impact of Orphan Drugs in the US: A 20072013 MIDAS Sales Data Analysis
    Divino, Victoria
    Dekoven, Mitch
    Wang, Weiying
    Kleinrock, Michael
    Harvey, R. Donald
    Wade, Rolin L.
    Kaura, Satyin
    BLOOD, 2014, 124 (21)
  • [46] Budget-impact of drugs for orphan diseases (orphan drugs) in the Israeli health basket: a longitudinal analysis
    Morginstin, Tal
    Hammerman, Ariel
    Triki, Noa
    Weinreb, Baruch
    ISRAEL JOURNAL OF HEALTH POLICY RESEARCH, 2019, 8 (01):
  • [47] Use of Titration as a Therapeutic Individualization Strategy: An Analysis of Food and Drug Administration-Approved Drugs
    Schuck, Robert N.
    Pacanowski, Michael
    Kim, Sarah
    Madabushi, Rajanikanth
    Zineh, Issam
    CTS-CLINICAL AND TRANSLATIONAL SCIENCE, 2019, 12 (03): : 236 - 239
  • [48] Varying results of early benefit assessment of newly approved pharmaceutical drugs in Germany from 2011 to 2017: A study based on federal joint committee data
    Peinemann, Frank
    Labeit, Alexander
    JOURNAL OF EVIDENCE BASED MEDICINE, 2019, 12 (01) : 9 - 15
  • [49] BUDGET IMPACT ANALYSIS OF INCLUDING SACUBITRIL/VALSARTAN IN THE NATIONAL FORMULARY FOR THE TREATMENT OF HEART FAILURE WITH REDUCED EJECTION FRACTION (HFREF) IN THAILAND
    Ratanasumawong, K.
    Piyayotai, D.
    Makarawate, P.
    VALUE IN HEALTH, 2022, 25 (01) : S107 - S107
  • [50] The economical impact of new anti-infective drugs on the drug budget of a surgical intensive care unit
    Hoppe-Tichy, T.
    Weigand, M. A.
    INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS, 2007, 29 : S388 - S388
12345